AD/PD 2026 Archives - PharmaDeviceNews

What Spear Bio’s new pTau 217 assay reveals about where Alzheimer’s biomarker detection is heading

By Pallavi Madhiraju on March 24, 2026 Medical Devices & Diagnostics

Spear Bio debuts BD-pTau 217, alpha-synuclein and pS129-a-syn assays at AD/PD 2026. What the claims mean for Alzheimer’s and Parkinson’s research. Read the analysis.

Why Roche’s Phase III bet on prasinezumab is bigger than its Phase IIb result suggests

By Pallavi Madhiraju on March 23, 2026 Pharma & Biotech

Roche and BMS present updated prasinezumab and BMS-986446 data at AD/PD 2026. What it means for Phase III plans and tau targeting. Read the analysis.

C2N Diagnostics advances PrecivityTauDx programme as tangle biomarker gains Phase 3 evidence

By Pallavi Madhiraju on March 22, 2026 Medical Devices & Diagnostics

C2N’s eMTBR-tau243 plasma assay shows independent prognostic value in Phase 3 Evoke data. What this means for Alzheimer’s patient selection. Read the analysis.